{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:45:03Z","timestamp":1788245103009,"version":"build-2803163510"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    The ataxia telangiectasia and rad3-related-checkpoint kinase 1 (ATR-CHK1) pathway is involved in DNA damage responses in many cancer cells. ATR inhibitors have been used in clinical trials in combination with radiation or chemotherapeutics; however, their effects against bladder cancer remain unclear. Here, the efficacy of combining gemcitabine with the novel ATR inhibitor AZD6738 was investigated\n                    <jats:italic>in vitro<\/jats:italic>\n                    in three bladder cancer cell lines (J82, T24, and UM-UC-3 cells). The effects of gemcitabine and AZD6738 on cell viability, clonogenicity, cell cycle, and apoptosis were examined. The combined use of gemcitabine and AZD6738 inhibited the viability and colony formation of bladder cancer cells compared to either treatment alone. Gemcitabine (5 nM) and AZD6738 (1 \u03bcM) inhibited cell cycle progression, causing cell accumulation in the S phase. Moreover, combined treatment enhanced cleaved poly[ADP-ribose]-polymerase expression alongside the number of annexin V-positive cells, indicating apoptosis induction. Mechanistic investigations showed that AZD6738 treatment inhibited the repair of gemcitabine-induced double-strand breaks by interfering with CHK1. Combining AZD6738 with gemcitabine could therefore be useful for bladder cancer therapy.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0266476","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T14:04:02Z","timestamp":1649772242000},"page":"e0266476","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-0281","authenticated-orcid":true,"given":"Makoto","family":"Isono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"issue":"16","key":"pone.0266476.ref001","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"MI Milowsky","year":"2016","journal-title":"J Clin Oncol."},{"issue":"9","key":"pone.0266476.ref002","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11912-014-0404-2","article-title":"Optimal treatment for metastatic bladder cancer","volume":"16","author":"EM Carballido","year":"2014","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"pone.0266476.ref003","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"A Dash","year":"2006","journal-title":"Cancer"},{"issue":"10031","key":"pone.0266476.ref004","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"JE Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"6835","key":"pone.0266476.ref005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer","volume":"411","author":"JH Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"pone.0266476.ref006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"A Sancar","year":"2004","journal-title":"Annu Rev Biochem"},{"issue":"7267","key":"pone.0266476.ref007","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"SP Jackson","year":"2009","journal-title":"Nature"},{"issue":"5","key":"pone.0266476.ref008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"J Bartek","year":"2003","journal-title":"Cancer Cell"},{"issue":"7381","key":"pone.0266476.ref009","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"CJ Lord","year":"2012","journal-title":"Nature"},{"key":"pone.0266476.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0473-1","article-title":"Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine","volume":"36","author":"M Isono","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"pone.0266476.ref011","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"MJ O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"issue":"2","key":"pone.0266476.ref012","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.18632\/oncotarget.6482","article-title":"ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer","volume":"7","author":"CC Li","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"pone.0266476.ref013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249715","article-title":"PARP Inhibition Increases the Reliance on ATR\/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness","volume":"21","author":"P Gralewska","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"pone.0266476.ref014","article-title":"Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer","volume":"22","author":"J Hur","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0266476.ref015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"H Sheng","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"pone.0266476.ref016","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression","volume":"17","author":"Y Wallez","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"pone.0266476.ref017","first-page":"6110","article-title":"Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"P Huang","year":"1991","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0266476.ref018","first-page":"533","article-title":"Cellular elimination of 2\u2019,2\u2019-difluorodeoxycytidine 5\u2019-triphosphate: a mechanism of self-potentiation","volume":"52","author":"V Heinemann","year":"1992","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0266476.ref019","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12864-015-1450-3","article-title":"The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies","volume":"16","author":"J Earl","year":"2015","journal-title":"BMC Genomics"},{"key":"pone.0266476.ref020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"11","key":"pone.0266476.ref021","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"P Workman","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"pone.0266476.ref022","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"A Ciccia","year":"2010","journal-title":"Mol Cell"},{"issue":"8","key":"pone.0266476.ref023","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrg2380","article-title":"Single-strand break repair and genetic disease","volume":"9","author":"KW Caldecott","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"40","key":"pone.0266476.ref024","doi-asserted-by":"crossref","first-page":"67754","DOI":"10.18632\/oncotarget.18834","article-title":"Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor","volume":"8","author":"R Montano","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"pone.0266476.ref025","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.dnarep.2008.06.018","article-title":"Comparison of nonhomologous end joining and homologous recombination in human cells","volume":"7","author":"Z Mao","year":"2008","journal-title":"DNA Repair (Amst)"},{"issue":"5","key":"pone.0266476.ref026","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clon.2014.02.004","article-title":"DNA double-strand break repair in a cellular context","volume":"26","author":"A Shibata","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"pone.0266476.ref027","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrm2851","article-title":"Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis","volume":"11","author":"ME Moynahan","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"pone.0266476.ref028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctro.2018.06.001","article-title":"PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours","volume":"12","author":"MT Dillon","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"pone.0266476.ref029","article-title":"Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.","author":"ST Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"pone.0266476.ref030","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models","volume":"123","author":"CR Dunlop","year":"2020","journal-title":"Br J Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T14:04:38Z","timestamp":1649772278000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266476"}},"subtitle":[],"editor":[{"given":"Robert W","family":"Sobol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266476","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}